UTHR insider Form 4 details 8,000 options exercised, share sales
Rhea-AI Filing Summary
United Therapeutics Corp Chairperson and CEO, who is also a director, reported option exercises and related stock sales in a Form 4 filing. On 11/20/2025 and 11/21/2025, the reporting person exercised 4,000 stock options on each day at an exercise price of $120.26 per share and sold the resulting shares in multiple open‑market transactions around $473–$480 per share, using weighted average prices.
The transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan entered on May 2, 2025, which will continue until the earlier of the exhaustion of a tranche of 294,000 stock options expiring on March 15, 2026 or December 31, 2025. Following the reported transactions, the reporting person holds 130 shares of common stock directly, additional shares indirectly through a spouse and several family trusts, and stock options to purchase 74,000 shares at $120.26 per share.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,500 | $473.3145 | $710K |
| Sale | Common Stock | 2,450 | $475.4215 | $1.16M |
| Sale | Common Stock | 50 | $476.07 | $24K |
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,000 | $476.8032 | $477K |
| Sale | Common Stock | 2,167 | $478.3169 | $1.04M |
| Sale | Common Stock | 833 | $480.4422 | $400K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. This transaction was executed in multiple trades at prices ranging from $476.74 to $477.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $477.77 to $478.675. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $480.18 to $480.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $472.95 to $473.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $475.02 to $476.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
FAQ
What insider transaction did United Therapeutics (UTHR) report in this Form 4?
The Form 4 reports that the Chairperson and CEO of United Therapeutics, who is also a director, exercised stock options and sold the underlying shares of common stock on 11/20/2025 and 11/21/2025.
How many United Therapeutics (UTHR) stock options were exercised and at what price?
The reporting person exercised 4,000 stock options on 11/20/2025 and another 4,000 stock options on 11/21/2025, each at an exercise price of $120.26 per share, from options expiring on March 15, 2026.
Was the United Therapeutics (UTHR) insider trading under a Rule 10b5-1 plan?
Yes. The filing states that the option exercises and sales were made under a pre‑arranged Rule 10b5‑1 trading plan entered into on May 2, 2025. The plan will continue until the earlier of the exhaustion of a 294,000 stock option tranche expiring on March 15, 2026 or December 31, 2025.
What indirect holdings of United Therapeutics (UTHR) stock are reported in the Form 4?
The filing lists indirect ownership of 166 shares through a spouse and additional indirect holdings of 324,518, 258,117, 45,596, and 15,962 shares of common stock through various family trusts, with differing trustee and beneficiary roles described in the footnotes.